The short version of synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-02. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
The vast majority of plants are C3, meaning they photorespire when necessary. Certain species of plants or algae have mechanisms to lower the uptake of molecular oxygen by RuBisCO. These are commonly referred to as Carbon Concentrating Mechanisms (CCMs), as they increase the concentration of CO2 so that RuBisCO is less likely to produce glycolate through reaction with O2.
== Malignant neoplasm of digestive organs and peritoneum (150–159) == 150 Malignant neoplasm of esophagus 151 Malignant neoplasm of stomach 152 Malignant neoplasm of small intestine, including duodenum 153 Malignant neoplasm colon 154 Malignant neoplasm of rectum, rectosigmoid junction, and anus 155 Malignant neoplasm of liver and intrahepatic bile ducts 156 Malignant neoplasm of gallbladder and extrahepatic bile ducts 157 Malignant neoplasm of pancreas 158 Malignant neoplasm of retroperitoneum and peritoneum 159 Malignant neoplasm of other and ill-defined sites within the
Fonterra's whey proteins have been key ingredients in foods and nutritional products sold around the world, including sports, medical, and beverage applications, and Fonterra continues to be a leading global supplier of whey protein.
Sources: en.wikipedia.org
Druze, like some Christians, believe that Elijah came back as John the Baptist, or as Saint George, since they belief in reincarnation and the transmigration of the soul, Druze believe that El Khidr and John the Baptist are one and the same. Saint George is described as a prophetic figure in Druze sources; and in some sources he is identified with Elijah or Mar Elias, and in others as al-Khidr. Druze believe that Elijah came back as John the Baptist and as Saint George, and the Druze version of the story of al-khidr was syncretized with the story of Saint George and the Dragon. The shrine of al-Khidr is located in the village of Kafr Yasif near the city of Acre on the Mediterranean coast. It is considered one of the most famous shrines in Druze religion. The prophet's name is "Sidna Abu Ibrahim" and he is nicknamed Nabi Al-Khidr (the Green One). Al-Khidr is identified with Elijah the prophet and, according to Druze belief, is one of the founders of their religion. The nickname El-Khidr (the Green One) comes from the belief that his memory will always be fresh like a green plant. Ziyarat al-Nabi al-Khidr is an Israeli Druze festival called Ziyara celebrated on 25 January which is officially recognized in Israel as a public holiday for Druzes, the celebration starts on 24 January and concludes on 25 January, with many religious leaders from all the religions in Israel, and also political leaders (occasionally also the PM), coming to congratulate the Israeli Druze community during their festivities at the Maqam Al-Khidr in Kafr Yasif.
May improve mood Strengthens and enlarges the heart muscle, to improve its pumping efficiency and reduce the resting heart rate, known as aerobic conditioning May improve circulation efficiency and reduce blood pressure May help maintain independence in later life Increases the total number of red blood cells in the body, facilitating transport of oxygen Improves mental health, including reducing stress and lowering the risk of depression, as well as increased cognitive capacity. Increases the synthesis of brain-derived neurotrophic factor (BDNF), which is thought to contribute to the cognitive benefits of regular exercise. Slightly reduced depression may also be observed, especially if aerobic exercises are used as additional treatment for patients with a hematological malignancy Reduces the risk for diabetes (One meta-analysis has shown, from multiple conducted studies, that aerobic exercise does help lower Hb A1Clevels for type 2 diabetics.) Moderates the risk of death due to cardiovascular problems Promotes weight loss Reduces the risk of osteoporosis May improve episodic memory
== History == The first recorded beneficial effects of using modified atmosphere date back to 1821. Jacques Étienne Bérard, a professor at the School of Pharmacy in Montpellier, France, reported delayed ripening of fruit and increased shelf life in low-oxygen storage conditions. Controlled atmosphere storage (CAS) was used from the 1930s when ships transporting fresh apples and pears had high levels of CO2 in their holding rooms in order to increase the shelf life of the product. In the 1970s MA packages reached the stores when bacon and fish were sold in retail packs in Mexico. Since then development has been continuous and interest in MAP has grown due to consumer demand.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.